Lyceum Capital Partners has announced a recommended cash offer of 78p per share to shareholders for Synexus Clinical Research Plc. AIM-listed Synexus is the largest European-headquartered business recruiting patients for late phase clinical trials on behalf of pharmaceutical and biotechnology companies. The offer values the company at just over £18m.
Shares are sold by shares were held by CapMan Buyout X Fund A and CapMan Buyout X Fund B
Advent made a takeover offer of 165 pence per share in cash, which represents a 34% premium in July
Business strategy platform will expand its product and triple its team size
Fund targets companies operating in the healthcare industry, primarily pharma, medtech and outsourced services